Back to Trials
NCT05010603RecruitingAccepts Healthy Volunteers

Late Onset Alzheimer's Disease

Columbia University

Start Date

11/15/2016

Completion Date

4/30/2027

Summary

The goal of this study is to is to focus on the genetic influences on Alzheimer's Disease (AD) risk. The investigators are looking for families and/or individuals (affected or unaffected) of any ethic background (African American, Caucasian, and Hispanics) with a family history of AD and willing to participate.

Detailed Description

The purpose of this study is to focus on the genetic influences on Alzheimer's disease (AD) risk. Specifically, the investigators hypothesize that one or more genes, other than the previously identified susceptibility gene apolipoprotein-E (APOE), or the 3 genes associated with early-onset familial AD, presenilin-1 (PS-1), presenilin-2 (PS-2) or B-amyloid precursor protein (APP), increase the risk of AD in families with multiple individuals affected with AD. The investigators propose to test this hypothesis by performing genetic linkage analysis in order to detect the chromosomal location of genes that may increase the risk of Alzheimer's disease. In addition, the investigators will study genes known to increase the risk of Alzheimer's disease and other related disorders such as early onset AD, Pick disease, corticobasal degeneration, progressive supranuclear palsy, and familial frontotemporal dementia with parkinsonism and Lewy Body Dementia.

Eligibility Criteria

Age Range: 55 years to No maximum

Inclusion Criteria: * Established diagnosis of definite or probable AD or have a diagnosis of a related neurodegenerative disorder such as Frontotemporal Dementia (FTD) or Lewy Body Dementia (LBD) (will also recruit sporadic FTD and LBD) cases. * a living sibling with probable or possible AD; * a third living relative affected with AD (onset age 50 or older) or unaffected (60 or older); * participants in the proband's generation with an identified companion serving as an informant; * participants who have capacity to consent or participants lacking capacity to consent with a surrogate/proxy in place to provide consent. Exclusion Criteria: * failure to identify an appropriate informant; * uncertainty of the clinical diagnosis of Alzheimer's disease or other related disorder; * discovery of additional diagnosis that could account for the clinical manifestations; * unwillingness to participate; * failure to identify a living sibling with AD or other related disorder (except in the cases of sporadic FTD and sporadic LBD); * participants lacking the capacity to consent who do not have a surrogate or proxy or next of kin to provide consent.

Interventions

GENETIC

Blood Draw

OTHER

Late Onset Alzheimer's Disease (LOAD) Neuropsychological Battery Test

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Alzheimer Disease

Locations

University of Washington

Washington D.C., District of Columbia 98105

United States

University of Miami

Miami, Florida 33124

United States

Rush University

Aurora, Illinois 60612

United States

Indiana University

Bloomington, Indiana 47405

United States

NCRAD at Indiana University

Indianapolis, Indiana 46202

United States

Mayo Clinic

Rochester, Minnesota 55901

United States

Joanne Norton

St Louis, Missouri 63130

United States

Columbia University Irving Medical Center

New York, New York 10032

United States

North Carolina State University

Raleigh, North Carolina 27695

United States

University of Pittsburgh

Pittsburgh, Pennsylvania 15213

United States

University of Texas Southwestern

Dallas, Texas 75390

United States

University of Washington

Seattle, Washington 98195

United States